DGCRF Diagnocure Inc (CE)

Appointment Targeting Next Steps to Increasing Shareholder Value

QUEBEC CITY, Aug. 20, 2013 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR)
(OTCQX: DGCRF), a life sciences company developing and commercializing
high?value cancer diagnostic tests, today announced the appointment of
Mr. Richard Bordeleau as Senior Advisor to the Company effective
September 1, 2013. Mr. Bordeleau will act as an executive in residence
and report directly to DiagnoCure's board of directors. In
collaboration with Company management, Mr. Bordeleau's initial mandate
will be to identify and implement short term actions aimed at
increasing shareholder value, and also to evaluate mid to long term
scenarios optimizing corporate value.

Mr. Bordeleau joins DiagnoCure, following a highly successful
international career in the life sciences industry. During his term as
President of Atrium Innovations from 2000 to 2007, the company
experienced sustainable double-digit organic growth through direct
sales combined with international license and distribution agreements,
augmented by multiple accretive acquisitions in North America and
Europe. Mr. Bordeleau also more recently contributed to the growth of
BioCad Medical, positioning the company as a leader in CADCAM
dentistry. BioCad Medical was purchased by Nobel Biocare 18 months
after he joined the company. Mr. Bordeleau currently manages
investments in start-up companies together with members of Anges
Quebec, a network of business angels where he initiated investments in
life sciences as responsible of the health and well-being sector.

"We are extraordinarily pleased that Mr. Bordeleau will be joining the
DiagnoCure team. His strong track record of growing companies and
creating value for shareholders is a powerful testament to his strength
in successfully negotiating and closing international licensing and
distribution agreements, and implementing value-creating
acquisitions," said Dr. Yves Fradet, Chairman of the Board.

"Reporting directly to the Board, Mr. Bordeleau's business acumen will
complement the scientific strengths of DiagnoCure's management team and
the clinical insight of our Chairman. The board has given Richard
significant powers to act as executive in residence in the creation of
both a long-term vision for success and a short-term improvement of
shareholder value," added Dr. Vincent Zurawski, DiagnoCure's Lead
Director.

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. Previstage^TM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license on PCA3 to Gen?Probe, now a wholly?owned
subsidiary of Hologic Inc., operating as Hologic Gen?Probe, for the
development and commercialization of a prostate cancer test,
DiagnoCure's proprietary molecular biomarker. Hologic Gen?Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the United States. For
more information, please visit www.diagnocure.com.

Forward?looking statements

This release contains forward?looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward?looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward?looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward?looking statements contained herein unless required by the
applicable securities laws and regulations.

SOURCE DiagnoCure inc.